Immuneering Corporation (IMRX)

Immuneering to Present at the 41st Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Immuneering Presents Data at 2026 AACR Conference on Pancreatic Cancer Supporting Atebimetinib's Mechanisms Designed to Extend Survival in Pancreatic Cancer

Immuneering to Present at the ESMO Congress 2026

Squarepoint Ops LLC Has $288,000 Holdings in Immuneering Corporation $IMRX

Immuneering to Present at the AACR Conference on Pancreatic Cancer, Highlighting Atebimetinib's Dual Mechanism for Extended Survival

Immuneering to Participate in Upcoming Investor Conferences

Immuneering Comments on Today's FDA Approval in Second-Line Metastatic Pancreatic Cancer, Reiterates Focus on First-Line Patients

Here Are Thursday’s Top Wall Street Analyst Research Calls: AppLovin, Charles River, Global Payments, HubSpot, Insulet Corporation, Roper Technologies, Sabra Health Care, Western Digital, Zillow Group, and More

Immuneering Reports Second Quarter 2026 Financial Results and Provides Business Updates

Immuneering: A Third (Much Cheaper) Way To Invest In The RAS-RAF-MEK-ERK 'Revolution'

Publication in Cancer Research Details Atebimetinib's Broad, Durable Preclinical Activity and Favorable Tolerability Across RAS- and RAF-Mutant Tumors via Deep Cyclic Inhibition

Immuneering Corporation Announces Grants of Inducement Awards

Immuneering Corporation Announces Grants of Inducement Awards

Immuneering (IMRX) Upgraded to Buy: Here's What You Should Know